(177)Lu-PSMA demonstrated high absorbed tumor doses (median, 3.3 mGy/MBq) as compared to normal organs. Parotid glands received higher doses (1.3 mGy/MBq) than kidneys (0.8 mGy/MBq). All patients tolerated the therapy without any acute adverse effects. Except mild reversible xerostomia in ...
Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomesdoi:10.1007/s40291-024-00699-wWhilst prostate cancer is the fourth most common cancer globally, effective therapies for patients with advanced disease are lacking. In...
Besides Lutetium-177 PSMA Therapy for prostate care, Farrer Park Hospital also offers Focal Therapy, anon-invasive procedure that treats early-stage prostate cancer using high intensity focused ultrasound. For non-cancerous enlargement of the prostate, the Prolieve® Therm...
Additionally, higher prostate-specific antigen (PSA) response rates were observed in the PSMA-617 group, reflecting the therapy’s effectiveness. The treatment was generally well-tolerated, with manageable side effects such as fatigue, bone marrow toxicity, and mild renal impairment. These findings ...
It's not chemotherapy. It's the FIRST and ONLY PSMA+ targeted radioligand therapy. Find out if PLUVICTO could be the next step for you or a loved one. Follow these links to explore why: If you or a loved one has started on PLUVICTO, here's what you need to know: ...
suspected metastasis who are candidates for initial definitive therapy; with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level; and for selection of patients with metastatic prostate cancer, for whom lutetium Lu 177 vipivotide tetraxetan PSMA-directed therapy is indicated...
Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res 2015; 5: 1–8. Article Google Scholar Heck MM, Retz M, D’Alessandria C, Rauscher I, Scheidhauer K, Maurer T et al....
Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes 来自 Springer 喜欢 0 阅读量: 17 作者:H Nguyen,K Hird,J Cardaci,S Smith,NP Lenzo 展开 摘要: Whilst prostate cancer is the fourth most common cancer ...
Lutetium-177-PSMA (Lu-PSMA), a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA), enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer (mCRPC). In a recent single-arm phase II trial and a subsequent expansion ...
PSMA‐617radioligand therapyMetastatic castration‐resistant prostate cancer (mCRPC) remains a challenging condition to treat despite recent advancements. This retrospective study aimed to assess the activity and tolerability of Lutetium‐177 (Lu‐177) PSMA‐617 radioligand therapy (RLT) in mCRPC patients...